{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-23-000040","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.336001+00:00","generated_at":"2026-06-09T00:05:29.141086+00:00","sec_items":["1.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Akebia extends loan maturity to March 2025, removes SOFR cap","bullets":["Extended maturity of $35M Term Loans from Nov 2024 to March 31, 2025.","Principal payments deferred until Oct 31, 2024, then monthly installments.","Removed 3.35% SOFR cap; interest now SOFR+0.3%+7.5% (~13.15% at amendment).","Prior capped rate was ~11.15%; removal increases borrowing cost."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-23-000040","json":"https://secwatch.observer/filing/0001517022-23-000040.json","markdown":"https://secwatch.observer/filing/0001517022-23-000040.md","text":"https://secwatch.observer/filing/0001517022-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000040/0001517022-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000040/akba-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:05:29.141086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ededcd6b18c22755822a644e6998ca38f94269c","claim":"Akebia Therapeutics, Inc. amended Fourth Amendment to Loan Agreement with BioPharma Credit PLC, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP valued at $35.0 million (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023 (the “Fourth Amendment Effective Date”), Akebia Therapeutics, Inc. (the “Company”), BioPharma Credit PLC (the “Collateral Agent”), BPCR Limited Partnership (as a “Lender”) and BioPharma Credit Investments V (Master) LP (as a “Lender”) entered into the Fourth Amendment to Loan Agreement (the “Fourth Amendment”), which amends certain provisions of the Loan Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702223000040/0001517022-23-000040-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"BioPharma Credit PLC, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP"},{"label":"Value","value":"$35.0 million"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}